A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants

Exclusion Criteria

• •History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disorders. - Abnormal blood pressure
• •A clinically significant ECG abnormality at screening.
• •Evidence of active or latent tuberculosis (TB).
• •Symptomatic herpes zoster within 3 months prior to screening
• •Alanine transaminase (ALT) \>1 times upper limit of normal (ULN).
• •Total bilirubin \>1.5x ULN \[isolated total bilirubin \>1.5x ULN is acceptable if total bilirubin is fractionated and direct bilirubin \<35- percentage (%)\].
• •History of malignancy.
• •Participants with known Corona virus disease-2019 (COVID-19) positive contacts as per local/site Guidelines
• •Prior moderate/severe COVID-19 infection requiring oxygen supplementation or admission to hospital.
• •Live vaccine(s) within 1 month prior to screening or plan to receive such vaccines during the study.
• •Past or intended use of over-the-counter or prescription medication including herbal medications within 7 days prior to dosing
• •The participant has participated in a clinical trial and has received an investigational product within 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product and dosing.
• •Current enrolment or past participation in this clinical study
• •Presence of Hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention
• •Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
• •Positive hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study
• •Positive pre-study drug/alcohol screen
• •Regular use of known drugs of abuse, including tetrahydrocannabinol.
• •Positive Human immunodeficiency virus (HIV) antibody test
• •Positive smoke breathalyzer levels indicative of smoking history at screening and each in-house admission to the clinical research unit or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
• •Estimated glomerular filtration rate (eGFR) of less than (\<) 90 (millilitre/minute) mL/min/1.73 m2 and / or Urine Albumin Creatinine (UACR) of \>30 milligram per gram (mg/g) at screening
• •A positive confirmation of SARS-CoV-2 infection or signs and symptoms suggestive of SARS-CoV-2 at screening or pre-dose
• •The participant has a phobia to needles
• •An average weekly alcohol intake of \> 14 units.
• •For Part 2:
• •History of benign skin conditions including but not limited to photosensitivity, atopic dermatitis, chronic eczema, psoriasis, urticaria, vitiligo, post-inflammatory hyperpigmentation, or keloid or hypertrophic scaring that in the opinion of the Investigator would impact study participation.
• •History or presence of excessive bleeding or coagulation disorders.
• •History of adverse reaction to local anesthetic.
• •The presence of widespread acne, freckles, naevi, tattoos, birthmarks, piercings, scarring or other skin variations within the proposed Ultraviolet B (UVB) exposure challenge area
• •Direct UV exposure to the areas of the body to be studied within 2 weeks.
• •Unable to refrain from exposure to extended and direct sunlight or use of artificial tanning devices, self-tanning products, sun blocking products or other topical products (including moisturizers and makeup) on the areas of the body to be studied.